Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data From 3744 Depressed Patients
J Clin Psychiatry 1998;59(10):502-508
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Venlafaxine hydrochloride, a structurally novel
antidepressant, is also the first nontricyclic serotonin/norepinephrine reuptake
inhibitor. Although venlafaxine has an overall side effect and safety profile that is
comparable to other newer antidepressants, it can cause both transient and sustained
elevations of supine diastolic blood pressure (SDBP), probably the result of noradrenergic
Method: Presented here is a meta-analysis of original data on blood
pressure, using both random effects and a multivariate survival analyses. The sample
consisted of 3744 patients with major depression who were studied in controlled clinical
trials comparing venlafaxine with imipramine and/or placebo. Patients were treated for 6
weeks of acute phase therapy; some responders received up to 1 year of continuation
Results: Venlafaxine and imipramine were associated with small, but
statistically significant, increases in SDBP during acute phase therapy. When compared
with imipramine and placebo, venlafaxine was also associated with a greater proportion of
persistent elevations of SDBP during continuation therapy. The effect of venlafaxine was
highly dose dependent, and the incidence of elevated SDBP was statistically and clinically
significant only at dosages above 300 mg/day. Venlafaxine did not adversely affect the
control of blood pressure for patients with preexisting high blood pressure or elevated
Conclusion: Venlafaxine has a dose-dependent effect on SDBP that is
clinically significant at high dosages. Concern about blood pressure effects should not
deter first-line use of this effective antidepressant, although more extensive studies of
patients with cardiovascular diseases are still necessary.